“Inflammatory or non-inflammatory pain in inflammatory arthritis – How to differentiate it?”

Sarzi-Puttini, Piercarlo; Pellegrino, Greta; Giorgi, Valeria; Bongiovanni, Sara Francesca; Varrassi, Giustino; Di Lascio, Simona; Fornasari, Diego; Sirotti, Silvia; Di Carlo, Marco; Salaffi, Fausto

doi:10.1016/j.berh.2024.101970

Best Practice & Research Clinical Rheumatology

2024

DOI: 10.1016/j.berh.2024.101970

|View full text |Cite

“Inflammatory or non-inflammatory pain in inflammatory arthritis – How to differentiate it?”

Piercarlo Sarzi-Puttini,

Greta Pellegrino,

Valeria Giorgi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Celecoxib in rheumatic diseases: possibilities and prospects. Brief descriptive survey

Karateev

2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Chronic pain is the main manifestation of rheumatic diseases (RD), it determines the main complaints and worsens the quality of life of patients. The problem of effective control of chronic pain in rheumatology remains a current issue despite the successes in the development of new drugs for pathogenetic therapy, especially in immunoinflammatory RD. For example, 40-50% of patients with rheumatoid arthritis (RA), even those receiving biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors, require analgesics. According to several population studies, about 50% of patients with the most common RD, osteoarthritis (OA) are forced to take various analgesics on a regular basis.The most popular class of analgesics with proven efficacy in RA, spondyloarthritis (SpA) and OA are non-steroidal anti-inflammatory drugs (NSAIDs). As has been shown in several meta-analyses, NSAIDs are superior to placebo and paracetamol in their therapeutic effect, are not inferior to opioids and are better tolerated overall. However, the use of NSAIDs can be associated with the development of dangerous adverse events (AEs), which requires careful monitoring of the patient's condition, considering comorbid diseases and risk factors. It is very important to choose a drug with a balanced ratio of efficacy and low risk of gastrointestinal and cardiovascular AEs. One such drug is celecoxib, whose therapeutic potential and relative safety have been confirmed in RA, SpA and OA. A differentiated approach to celecoxib prescription makes it possible to achieve a maximum therapeutic result with a minimum risk of AEs. For severe pain, treatment starts with a dose of 400 mg/day, followed by a switch to a maintenance dose of 200 mg/day.

show abstract

Celecoxib in rheumatic diseases: possibilities and prospects. Brief descriptive survey

Karateev

2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Pathophysiology and Evolving Treatment Options of Septic Arthritis: A Narrative Review

Kaye,

Greene,

Alvarez-Amado

et al. 2024

Cureus

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

“Inflammatory or non-inflammatory pain in inflammatory arthritis – How to differentiate it?”

Cited by 2 publications

References 63 publications

Celecoxib in rheumatic diseases: possibilities and prospects. Brief descriptive survey

Celecoxib in rheumatic diseases: possibilities and prospects. Brief descriptive survey

Pathophysiology and Evolving Treatment Options of Septic Arthritis: A Narrative Review

Contact Info

Product

Resources

About